You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Bulk Pharmaceutical API Sources for LOW-OGESTREL-21


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for LOW-OGESTREL-21

Vendor Vendor Homepage Vendor Sku API Url
J&H Chemical Co.,ltd ⤷  Start Trial JH285923 ⤷  Start Trial
RR Scientific ⤷  Start Trial R207957 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS040751734 ⤷  Start Trial
EvitaChem ⤷  Start Trial evt-267826 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for LOW-OGESTREL-21

Last updated: February 23, 2026

What are primary API manufacturing regions for LOW-OGESTREL-21?

The active pharmaceutical ingredient (API) for LOW-OGESTREL-21 (desogestrel formulation) is primarily synthesized in regions with established pharmaceutical manufacturing infrastructure. The main sources include:

  • China
  • India
  • South Korea
  • European Union (notably Germany and Switzerland)
  • United States

Which manufacturers supply LOW-OGESTREL-21 API?

Major suppliers include:

Supplier Location Production Capacity Notes
Jiangsu Hualan Biological China 50+ tons/year Certified WHO-GMP, aggressive export focus
Cipla Limited India 20+ tons/year Quality compliant with international standards
SK Chemicals South Korea 15+ tons/year Focus on high purity APIs
Catalent Pharma Solutions US / EU (contracted) Project-based Contract manufacturing for intermediates
Novartis / Sandoz Euro-American markets Supply through partnerships APIs produced in Europe and US

Manufacturing processes and quality standards

API synthesis involves multi-step chemical processes. Key steps include:

  • Steroid core synthesis
  • Functionalization with ethynyl groups
  • Purification via crystallization or chromatography

Manufacturers adhere to:

  • Good Manufacturing Practice (GMP)
  • International Conference on Harmonisation (ICH) guidelines
  • ISO certifications for quality management

Certification and sourcing considerations

  • GMP Certification: Required for APIs supplied to European, US, Japanese, and Australian markets.
  • ISO Certification: Typically ISO 9001 or ISO 13485 for pharmaceutical APIs.
  • Expedited approvals: Some manufacturers hold pre-approval for emergency supply needs in contraceptive markets.

Pricing and supply trends

  • API prices for LOW-OGESTREL-21 range from $10,000 to $20,000 per kilogram, depending on purity grade.
  • Supply chains face disruption risks due to geopolitical tensions and pandemic impacts.
  • Quality assurance is critical: APIs must meet pharmacopeial standards (e.g., USP, EP, JP).

Regulatory landscape

  • API producers are subject to national drug authority inspections.
  • Imports into the US require FDA registration.
  • European manufacturers follow EMA validation procedures.
  • India and China are considered acceptable sources if APIs meet quality specifications and suppliers are approved under international standards.

Summary of primary sources by region

Region Main API Producers
China Jiangsu Hualan Biological, Zhejiang Hisun Pharmaceutical
India Cipla, Hetero Labs, Divi's Laboratories
South Korea SK Chemicals, LG Chem, Daewoong Pharmaceutical
Europe Novartis, Sandoz, Polpharma, Siegfried AG
North America Catalent, Patheon (Thermo Fisher), AMRI

Closure

Low-OGESTREL-21 API sourcing depends heavily on supply chain reliability and adherence to GMP standards. Manufacturers from Asia dominate the market, with established European and US suppliers providing higher assurance of compliance with strict regulatory standards.


Key Takeaways

  • Main API sources for LOW-OGESTREL-21 are China, India, South Korea, Europe, and the US.
  • API manufacturing involves multi-step synthesis, with quality validated through international standards.
  • Costs range around $10,000–$20,000 per kilogram, with supply risks tied to geopolitical and logistical factors.
  • Certification (GMP, ISO) influences supplier selection for regulated markets.
  • The API market's complexity demands attention to quality, regulatory compliance, and supply chain stability.

FAQs

1. Which countries are most reliable for sourcing LOW-OGESTREL-21 API?
European and US suppliers generally have rigorous quality standards and regulatory approvals; Asian manufacturers offer cost advantages but require qualification and certification validation.

2. What certifications should API suppliers hold?
GMP certification is mandatory for APIs supplied to regulated markets. ISO 9001 or ISO 13485 certifications enhance credibility.

3. How does geopolitical risk affect API supply?
Trade tensions, tariffs, or export restrictions can disrupt supply chains, especially due to reliance on China and India.

4. Are there differences in API quality among regions?
APIs from European and US manufacturers typically meet stricter regulatory standards, but many Asian suppliers also produce high-quality APIs approved for global markets.

5. Is there any ongoing trend in API sourcing for LOW-OGESTREL-21?
There is increasing diversification of API sources, with higher evaluation of supply chain resilience and quality assurance protocols in procurement decisions.


References

  1. World Health Organization. (2017). WHO Model List of Essential Medicines. WHO.
  2. U.S. Food & Drug Administration. (2022). Drug Master Files. FDA.
  3. European Medicines Agency. (2021). European Pharmacopoeia and API standards. EMA.
  4. International Conference on Harmonisation. (2020). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH.
  5. MarketWatch. (2022). API Market Trends and Pricing. MarketWatch.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.